Anti-CNTN1 IgG3 induces acute conduction block and motor deficits in a passive transfer rat model.
Animals
Cell Adhesion Molecules, Neuronal
/ metabolism
Complement C1q
/ metabolism
Contactin 1
/ immunology
Cytokines
/ metabolism
Disease Models, Animal
Female
Guillain-Barre Syndrome
/ complications
Humans
Immunization, Passive
/ methods
Immunoglobulin G
/ pharmacology
Motor Disorders
/ chemically induced
Neural Conduction
/ drug effects
Optic Neuritis
/ blood
Ranvier's Nodes
/ drug effects
Rats
Rats, Inbred Lew
Reaction Time
/ drug effects
Recovery of Function
/ drug effects
Rotarod Performance Test
Statistics, Nonparametric
Anti-contactin-1
Autoantibody
CIDP
Complement deposition
Paranodopathy
Passive transfer
Journal
Journal of neuroinflammation
ISSN: 1742-2094
Titre abrégé: J Neuroinflammation
Pays: England
ID NLM: 101222974
Informations de publication
Date de publication:
05 Apr 2019
05 Apr 2019
Historique:
received:
11
09
2018
accepted:
25
03
2019
entrez:
7
4
2019
pubmed:
7
4
2019
medline:
6
8
2019
Statut:
epublish
Résumé
Autoantibodies against the paranodal protein contactin-1 have recently been described in patients with severe acute-onset autoimmune neuropathies and mainly belong to the IgG4 subclass that does not activate complement. IgG3 anti-contactin-1 autoantibodies are rare, but have been detected during the acute onset of disease in some cases. There is evidence that anti-contactin-1 prevents adhesive interaction, and chronic exposure to anti-contactin-1 IgG4 leads to structural changes at the nodes accompanied by neuropathic symptoms. However, the pathomechanism of acute onset of disease and the pathogenic role of IgG3 anti-contactin-1 is largely unknown. In the present study, we aimed to model acute autoantibody exposure by intraneural injection of IgG of patients with anti-contacin-1 autoantibodies to Lewis rats. Patient IgG obtained during acute onset of disease (IgG3 predominant) and IgG from the chronic phase of disease (IgG4 predominant) were studied in comparison. Conduction blocks were measured in rats injected with the "acute" IgG more often than after injection of "chronic" IgG (83.3% versus 35%) and proved to be reversible within a week after injection. Impaired nerve conduction was accompanied by motor deficits in rats after injection of the "acute" IgG but only minor structural changes of the nodes. Paranodal complement deposition was detected after injection of the "acute IgG". We did not detect any inflammatory infiltrates, arguing against an inflammatory cascade as cause of damage to the nerve. We also did not observe dispersion of paranodal proteins or sodium channels to the juxtaparanodes as seen in patients after chronic exposure to anti-contactin-1. Our data suggest that anti-contactin-1 IgG3 induces an acute conduction block that is most probably mediated by autoantibody binding and subsequent complement deposition and may account for acute onset of disease in these patients. This supports the notion of anti-contactin-1-associated neuropathy as a paranodopathy with the nodes of Ranvier as the site of pathogenesis.
Sections du résumé
BACKGROUND
BACKGROUND
Autoantibodies against the paranodal protein contactin-1 have recently been described in patients with severe acute-onset autoimmune neuropathies and mainly belong to the IgG4 subclass that does not activate complement. IgG3 anti-contactin-1 autoantibodies are rare, but have been detected during the acute onset of disease in some cases. There is evidence that anti-contactin-1 prevents adhesive interaction, and chronic exposure to anti-contactin-1 IgG4 leads to structural changes at the nodes accompanied by neuropathic symptoms. However, the pathomechanism of acute onset of disease and the pathogenic role of IgG3 anti-contactin-1 is largely unknown.
METHODS
METHODS
In the present study, we aimed to model acute autoantibody exposure by intraneural injection of IgG of patients with anti-contacin-1 autoantibodies to Lewis rats. Patient IgG obtained during acute onset of disease (IgG3 predominant) and IgG from the chronic phase of disease (IgG4 predominant) were studied in comparison.
RESULTS
RESULTS
Conduction blocks were measured in rats injected with the "acute" IgG more often than after injection of "chronic" IgG (83.3% versus 35%) and proved to be reversible within a week after injection. Impaired nerve conduction was accompanied by motor deficits in rats after injection of the "acute" IgG but only minor structural changes of the nodes. Paranodal complement deposition was detected after injection of the "acute IgG". We did not detect any inflammatory infiltrates, arguing against an inflammatory cascade as cause of damage to the nerve. We also did not observe dispersion of paranodal proteins or sodium channels to the juxtaparanodes as seen in patients after chronic exposure to anti-contactin-1.
CONCLUSIONS
CONCLUSIONS
Our data suggest that anti-contactin-1 IgG3 induces an acute conduction block that is most probably mediated by autoantibody binding and subsequent complement deposition and may account for acute onset of disease in these patients. This supports the notion of anti-contactin-1-associated neuropathy as a paranodopathy with the nodes of Ranvier as the site of pathogenesis.
Identifiants
pubmed: 30953561
doi: 10.1186/s12974-019-1462-z
pii: 10.1186/s12974-019-1462-z
pmc: PMC6450014
doi:
Substances chimiques
CNTN1 protein, human
0
Cell Adhesion Molecules, Neuronal
0
Cntnap1 protein, rat
0
Contactin 1
0
Cytokines
0
Immunoglobulin G
0
Complement C1q
80295-33-6
Types de publication
Journal Article
Langues
eng
Pagination
73Références
Lancet. 2005 Apr 16-22;365(9468):1406-11
pubmed: 15836889
Ann Neurol. 2008 Jun;63(6):782-9
pubmed: 18384168
Eur J Echocardiogr. 2011 Feb;12(2):90-7
pubmed: 20810448
Exp Neurol. 2012 Jan;233(1):534-42
pubmed: 22178332
Exp Neurol. 2012 Jun;235(2):513-6
pubmed: 22507308
Nat Methods. 2012 Jun 28;9(7):676-82
pubmed: 22743772
Neurology. 2012 Dec 4;79(23):2241-8
pubmed: 23100406
Ann Neurol. 2013 Mar;73(3):370-80
pubmed: 23280477
Clin Neurophysiol. 2013 Oct;124(10):1928-34
pubmed: 23639374
Muscle Nerve. 2014 Aug;50(2):257-61
pubmed: 24347162
J Biol Chem. 2014 Mar 14;289(11):7907-18
pubmed: 24497634
Front Immunol. 2014 Oct 20;5:520
pubmed: 25368619
J Neurol Neurosurg Psychiatry. 2015 Jul;86(7):720-8
pubmed: 25694474
Brain. 2015 Jun;138(Pt 6):1484-91
pubmed: 25808373
Brain. 2016 Jun;139(Pt 6):1700-12
pubmed: 27017186
Brain. 2016 Oct;139(Pt 10):2617-2630
pubmed: 27474220
Exp Neurol. 2017 Jan;287(Pt 1):84-90
pubmed: 27746185
J Neurol Neurosurg Psychiatry. 2017 Jun;88(6):465-473
pubmed: 28073817
J Neurol Neurosurg Psychiatry. 2018 Jun;89(6):627-635
pubmed: 29248893
Front Immunol. 2018 May 14;9:1029
pubmed: 29867996
N Engl J Med. 1977 Jan 20;296(3):125-31
pubmed: 831074